Therefore, we found that the response to anti‐PD‐1 and anti‐CTLA4 treatments was closely correlated with the expression levels of EMX2OS and TLN2 in ccRCC patients (Figure 7D,J). The gene discussed is TLN2; the disease is nonpapillary renal cell carcinoma.